CEL-SCI Corporation reported that its Multikine® (Leukocyte Interleukin, Injection) cGMP dedicated manufacturing facility commissioning has been completed. Originally constructed to supply Multikine for the world?s largest global pivotal Phase 3 trial in locally advanced squamous cell carcinoma of the head and neck, CEL-SCI?s facility has been expanded and upgraded in preparation for the Company?s submission of Multikine for regulatory approval and commercial scale manufacturing. In keeping with CEL-SCI Validation Master Plan, industry standards, International Society for Pharmaceutical Engineering (ISPE) guidelines, International Conference for Harmonization (ICH), and in compliance with regulatory guidelines, CEL-SCI undertook commissioning and qualifying the facility?s utilities, systems, and equipment.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.72 USD | +5.52% | +21.99% | -36.76% |
Apr. 23 | CEL-SCI Corporation Appoints Mario Gobbo as Board of Directors | CI |
Feb. 14 | CEL-SCI Corporation Reports Earnings Results for the First Quarter Ended December 31, 2023 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-36.76% | 87.99M | |
-3.23% | 88.14B | |
+1.45% | 40.51B | |
-14.43% | 31.67B | |
+51.20% | 24.62B | |
-14.85% | 15.65B | |
-13.87% | 12.07B | |
-7.87% | 11.97B | |
-39.40% | 11.61B | |
+5.62% | 8.81B |
- Stock Market
- Equities
- CVM Stock
- News CEL-SCI Corporation
- CEL-SCI Corporation Completes Commissioning of Its Multikine Manufacturing Facility for Commercial Scale Production of Head & Neck Cancer Drug